Lido Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Lido Advisors’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-64,000	Closed	-$260K	–	1031
2021 Q2	$260K	Hold	64,000	–	–	﹤0.01%	769
2021 Q1	$289K	Sell	64,000 -9,000	-12%	-$48.5K	0.01%	672
2020 Q4	$359K	Buy	+73,000	New	+$365K	0.01%	568

Other funds holding XERS

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Lido Advisors's XERS Position: Q3 2021 in Review

Lido Advisors sold out of Xeris Biopharma Holdings (XERS) in Q3 2021, closing a stake of 64,000 shares — an estimated $260K sold.

Lido Advisors first reported a position in XERS in Q4 2020 and held it in 3 quarters. The position peaked at $359K in Q4 2020. 70 funds tracked by Wall St. Rank hold XERS as of Q3 2021.

Lido Advisors reported no remaining Xeris Biopharma Holdings position as of Q3 2021 after selling out during the quarter.
Lido Advisors sold 64,000 Xeris Biopharma Holdings shares in Q3 2021, an estimated $260K.
Lido Advisors first reported a position in Xeris Biopharma Holdings in Q4 2020 and held it in 3 quarters.
Lido Advisors's Xeris Biopharma Holdings position peaked at $359K in Q4 2020.
70 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2021.

Based on Lido Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.